AI-generated analysis. Always verify with the original filing.
Zura Bio Limited reported full year 2025 financial results with net loss of $68.7 million, R&D expenses of $42.1 million, and cash and cash equivalents of $109.4 million as of December 31, 2025, alongside updates on ongoing Phase 2 tibulizumab trials and a February 2026 public offering raising $144 million gross proceeds, extending cash runway through at least end of 2028.
Event Type
Disclosure
Mandatory
Variant
8-K
(including Exhibit 99.1) shall not be deemed incorporated by reference into any other filing with Securities and Exchange Commission (the “SEC”) made by the Com
(including Exhibit 99.2) shall not be deemed incorporated by reference into any other filing with the SEC made by the Company, whether made before or after the
. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated March 19, 2026 99.2 Corporate Presentation, dated March 19,